---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001975"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:22:20.759593+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protalix and Chiesi receive positive CHMP opinion for PRX-102 (pegunigalsidase alfa) for Fabry disease

## Summary
- CHMP adopted positive opinion recommending marketing authorization for PRX-102 (pegunigalsidase alfa) for adult Fabry disease patients.
- PRX-102 is the first and only pegylated enzyme replacement therapy for Fabry disease.
- Clinical program includes Phase 3 BALANCE, BRIDGE, BRIGHT trials with over 400 years of exposure.
- Final European Commission decision on MAA expected in early May 2023.
- Protalix (PLX) and Chiesi Global Rare Diseases (Chiesi Group) collaboration.

## SEC filing metadata
- accession: 0001558370-23-001975
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023001975/0001558370-23-001975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023001975/plx-20230224x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001975
- JSON: https://secwatch.observer/filing/0001558370-23-001975.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.